Lunit receives $26M funding from Guardant Health
South Korean artificial intelligence (AI) software developer Lunit recentl...Read more on AuntMinnie.comRelated Reading: Lunit highlights Karolinska AI studies Lunit partners with Philips on chest AI software Lunit, Infinitt partner on Indonesian distribution deal Lunit touts study for COVID-19 imaging Lunit highlights AI lung cancer detection research
In conclusion, the aforementioned hub genes might play potential roles in translational medicine and might become promising therapeutic targets. Further in vitro and in vivo experimental studies are needed to evaluate the role of these hub genes in COVID-19.PMID:34441862 | DOI:10.3390/jcm10163567
Int Immunopharmacol. 2021 Jul 30;99:108012. doi: 10.1016/j.intimp.2021.108012. Online ahead of print.ABSTRACTALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the interfering co-medication may hamper the anti-cancer therapeutic management. Here, we present for the first time a drug interaction profile of ALK-TKIs, crizotinib and alectinib, and immunosuppressive agent cyclosporine A in kidney transplant recipients diagnosed with AL...
CONCLUSION: Novel immunotherapies are needed in cancer patients with resistance to or relapse after current immunotherapeutic drugs. Such new treatments may include targeted agents or monoclonal antibodies to overcome the immune-suppressive tumor microenvironment. The mode of combining the novel treatments, including vaccines, needs to be matched to the patient's immune status for achieving the maximum benefit. In this scenario, specific attention should be also paid nowadays to the immune intersection between COVID-19 and cancer.PMID:34301276 | DOI:10.1186/s13046-021-02023-4
Lunit is claiming that its artificial intelligence (AI) algorithm showed grea...Read more on AuntMinnie.comRelated Reading: Lunit partners with Philips on chest AI software Lunit, Infinitt partner on Indonesian distribution deal Lunit touts study for COVID-19 imaging Lunit highlights AI lung cancer detection research Lunit touts AI mammography studies
In conclusion, the MR exhibited the protective effects against age-related behavioral disorders, which could be partly explained by activating circulating FGF21 and promoting mitochondrial biogenesis, and consequently suppressing the neuroinflammation and oxidative damages. These results demonstrate that FGF21 can be used as a potential nutritional factor in dietary restriction-based strategies for improving cognition associated with neurodegeneration disorders. Senescent T Cells Cause Changes in Fat Tissue that are Harmful to Long-Term Health https://www.fightaging.org/archives/2021/04/senescent-t-cells-cause-...
Artificial intelligence (AI) software developer Lunit is making its chest imagin...Read more on AuntMinnie.comRelated Reading: Philips forms ultrasound AI partnership with DiA Can radiology AI save itself? AI improves lung cancer detection on x-rays Lunit touts study for COVID-19 imaging Lunit highlights AI lung cancer detection research
An artificial intelligence (AI) algorithm was able to predict patients' ris...Read more on AuntMinnie.comRelated Reading: AI enhances performance of CT lung cancer screening Better chest CT CAC reporting avoids unnecessary exams CT shows its value in the COVID-19 crisis Deep learning refines cardiac CT results CT CAC directs statin therapy in African Americans
Artificial intelligence (AI) software developer Lunit and RIS/PACS vendor Infinitt...Read more on AuntMinnie.comRelated Reading: Lunit touts study for COVID-19 imaging Lunit highlights AI lung cancer detection research Lunit touts AI mammography studies Infinitt readies new PACS release for RSNA 2019 Infinitt secures Fla. contract Infinitt inks agreement with ImagineSoftware
An artificial intelligence (AI) deep learning-based risk prediction model trained...Read more on AuntMinnie.comRelated Reading: CT lung screening rates plunge during COVID-19 pandemic Social factors affect CT lung screening compliance CT lung screening scans also work for bone density CT lung screening program falls short in China Radiomics can aid management of lung cancer patients
The objective of this study is to quantify the overall and cancer type-specific risks of subsequent primary cancers (SPCs) among adult-onset cancer survivors by first primary cancer (FPC) types and sex. Among 1,537,101 survivors (mean age, 60.4 years; 48.8% women), 156,442 SPC cases and 88,818 SPC deaths occurred during 11,197,890 person-years of follow-up (mean, 7.3 years). Among men, the overall risk of developing any SPCs was statistically significantly higher for 18 of the 30 FPC types, and risk of dying from any SPCs was statistically significantly higher for 27 of 30 FPC types as compared with risks in the general po...